Compare AVXL & PDLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | PDLB |
|---|---|---|
| Founded | 2004 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.9M | 405.9M |
| IPO Year | 2013 | 2021 |
| Metric | AVXL | PDLB |
|---|---|---|
| Price | $2.82 | $16.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 61.2K |
| Earning Date | 05-12-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 160.87 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $10.88 |
| 52 Week High | $13.99 | $18.01 |
| Indicator | AVXL | PDLB |
|---|---|---|
| Relative Strength Index (RSI) | 26.55 | 52.07 |
| Support Level | N/A | $15.84 |
| Resistance Level | $4.98 | $17.29 |
| Average True Range (ATR) | 0.28 | 0.31 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 8.85 | 51.52 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.